Multifocal Motor Neuropathy Overview

Save information for later
Sign Up

Learn About Multifocal Motor Neuropathy

What is the definition of Multifocal Motor Neuropathy?
Multifocal motor neuropathy (MMN) causes damage to the nerves in the arms and legs. Nerve damage begins in adulthood and slowly gets worse over time. One side of the body may be more affected than the other. Symptoms of MMN may include weakness in the hands and lower arms; cramping; involuntary contractions or twitching; wrist drop or foot drop, and wasting of the affected muscles. MMN is thought to be due to an abnormal immune response, but the underlying cause is not clear. Diagnosis is based on the symptoms, clinical exam, and specific laboratory testing. Guidelines for diagnosis have been published.
What are the alternative names for Multifocal Motor Neuropathy?
  • Multifocal motor neuropathy
  • MMN
  • MMNCB
  • Multifocal motor neuropathy with conduction block
Who are the top Multifocal Motor Neuropathy Local Doctors?
Elite in Multifocal Motor Neuropathy
Ryuji Kaji
Elite in Multifocal Motor Neuropathy
Ryuji Kaji
Tokushima, JP 

Ryuji Kaji practices in Tokushima, Japan. Mr. Kaji is rated as an Elite expert by MediFind in the treatment of Multifocal Motor Neuropathy. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Multifocal Motor Neuropathy, Deep Brain Stimulation, and Thymectomy.

Elite in Multifocal Motor Neuropathy
Eduardo Orazio-Nobile
Elite in Multifocal Motor Neuropathy
Eduardo Orazio-Nobile
Milan, IT 

Eduardo Orazio-Nobile practices in Milan, Italy. Mr. Orazio-Nobile is rated as an Elite expert by MediFind in the treatment of Multifocal Motor Neuropathy. His top areas of expertise are Chronic Demyelinizing Neuropathy with IgM Monoclonal, Chronic Polyradiculoneuritis, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Multifocal Motor Neuropathy
Susumu Kusunoki
Elite in Multifocal Motor Neuropathy
Susumu Kusunoki
Osaka, JP 

Susumu Kusunoki practices in Osaka, Japan. Mr. Kusunoki is rated as an Elite expert by MediFind in the treatment of Multifocal Motor Neuropathy. His top areas of expertise are Guillain-Barre Syndrome, Miller-Fisher Syndrome, Spinocerebellar Ataxia Type 8, and Multifocal Motor Neuropathy.

View All Doctors
What are the latest Multifocal Motor Neuropathy Clinical Trials?
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)
Enrollment Status: Recruiting
Publish Date: October 06, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy
Enrollment Status: Recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Other
Study Phase: Phase 3

Summary: The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center